How well flu, COVID-19, and other respiratory vaccines protect people in southeastern Michigan
Official title: RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
Funded at University of Michigan at Ann Arbor · NIH-11170372 · Data updated 2026-11-12
This project checks how well seasonal flu, COVID-19, and other respiratory vaccines protect people who visit clinics for coughs, colds, or breathing problems in southeastern Michigan.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 30, 2022 |
| Project end | September 29, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,310,713 |
| NIH project number | 5U01IP001193-04 |
| Project ID | NIH-11170372 on NIH RePORTER |
Who could benefit from this research
✓Could help
People of any age who go to participating outpatient clinics or testing centers in southeastern Michigan with symptoms of acute respiratory illness are ideal candidates.
✕Less likely to help
People without respiratory symptoms, those not seeking care, or individuals living outside the study region are unlikely to be eligible or directly benefit from participation.
What this research studies
If you take part, researchers will enroll people who come to participating outpatient clinics and testing centers with acute respiratory symptoms. They will collect swabs and blood samples and test for flu, COVID-19, RSV, and other respiratory viruses, while comparing vaccination status using a test-negative approach. The team will also analyze antibody responses and sequence viral genomes to see which virus strains are causing illness and whether vaccines are matching those strains. Enrollment focuses on clinics across multiple communities, including sites that serve populations disproportionately affected by respiratory infections.
Why it matters
Potential benefit: If successful, this work could help improve vaccine recommendations and better protect people from flu, COVID-19, and other respiratory viruses.
How similar studies have gone: The U.S. Flu VE Network has successfully used this test-negative surveillance approach for years, though adding antibody testing and whole-genome sequencing expands what can be learned.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Martin, Emily Toth — University of Michigan at Ann Arbor
- Study coordinator: Martin, Emily Toth
Related research
Other NIH-funded projects on the same topics.
-
Motivational interviewing to increase COVID-19 and flu vaccination
This project teaches primary care providers conversational skills to help more adults, especially those in vulnerable communities, feel comfortable getting COVID-19 and flu shots.
-
Platform to Measure How Well Flu and COVID-19 Vaccines Work in Underserved Arizona Communities
A research effort in Arizona will track how well flu and COVID-19 vaccines protect people in underserved communities, including diverse adults and immunocompromised individuals.
-
Credible vaccine protection measures for Flu, COVID-19, and other respiratory viruses in Texas ambulatory care
This project looks at how well flu and COVID-19 vaccines protect people from visiting clinics for acute respiratory illnesses in Central Texas.
-
Platform to Measure How Well Seasonal Flu, COVID-19, and Other Respiratory Vaccines Prevent Illness in Real-Life Settings
This grant supports a national effort to track how well respiratory vaccines work in everyday clinics and homes.
-
Vaccine effectiveness in Michigan: how well flu, COVID-19 and other respiratory vaccines work
This project tests how well vaccines against flu, COVID-19, and other respiratory viruses prevent medically attended illness in people visiting outpatient clinics in Southeastern Michigan.
-
How flu, COVID-19, and other respiratory virus vaccines protect against outpatient respiratory illness in Central Texas
This project measures how well flu, COVID-19, and other respiratory virus vaccines prevent people in Central Texas from getting sick enough to seek outpatient medical care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.